Joseph Lehar
Overview
Explore the profile of Joseph Lehar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
14382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Krueger A, Munck C, Dantas G, Church G, Galagan J, Lehar J, et al.
PLoS One
. 2016 Jan;
11(1):e0147651.
PMID: 26821252
Flux balance analysis (FBA) is an increasingly useful approach for modeling the behavior of metabolic systems. However, standard FBA modeling of genetic knockouts cannot predict drug combination synergies observed between...
12.
Reddy A, Growney J, Wilson N, Emery C, Johnson J, Ward R, et al.
PLoS One
. 2016 Jan;
11(1):e0146635.
PMID: 26731447
No abstract available.
13.
Gao H, Korn J, Ferretti S, Monahan J, Wang Y, Singh M, et al.
Nat Med
. 2015 Oct;
21(11):1318-25.
PMID: 26479923
Profiling candidate therapeutics with limited cancer models during preclinical development hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous patient responses for patient-selection strategies. We established ∼1,000 patient-derived...
14.
Reddy A, Growney J, Wilson N, Emery C, Johnson J, Ward R, et al.
PLoS One
. 2015 Sep;
10(9):e0138486.
PMID: 26378449
Death Receptor 5 (DR5) agonists demonstrate anti-tumor activity in preclinical models but have yet to demonstrate robust clinical responses. A key limitation may be the lack of patient selection strategies...
15.
Johansen L, DeWald L, Shoemaker C, Hoffstrom B, Lear-Rooney C, Stossel A, et al.
Sci Transl Med
. 2015 Jun;
7(290):290ra89.
PMID: 26041706
Currently, no approved therapeutics exist to treat or prevent infections induced by Ebola viruses, and recent events have demonstrated an urgent need for rapid discovery of new treatments. Repurposing approved...
16.
Wang K, Shrestha R, Wyatt A, Reddy A, Lehar J, Wang Y, et al.
PLoS One
. 2014 Jul;
9(7):e103050.
PMID: 25036042
Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation...
17.
Vora S, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al.
Cancer Cell
. 2014 Jul;
26(1):136-49.
PMID: 25002028
Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A combinatorial drug screen on multiple...
18.
Schoumacher M, Hurov K, Lehar J, Yan-Neale Y, Mishina Y, Sonkin D, et al.
Cancer Res
. 2014 Apr;
74(12):3294-305.
PMID: 24747911
Tankyrases (TNKS) play roles in Wnt signaling, telomere homeostasis, and mitosis, offering attractive targets for anticancer treatment. Using unbiased combination screening in a large panel of cancer cell lines, we...
19.
Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al.
Mol Cancer Ther
. 2014 Mar;
13(5):1117-29.
PMID: 24608574
Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects associated...
20.
Johansen L, Brannan J, Delos S, Shoemaker C, Stossel A, Lear C, et al.
Sci Transl Med
. 2013 Jun;
5(190):190ra79.
PMID: 23785035
Ebola viruses remain a substantial threat to both civilian and military populations as bioweapons, during sporadic outbreaks, and from the possibility of accidental importation from endemic regions by infected individuals....